2018 Bioelectronic Medicine Forum

March 22, 2018

Millennium Broadway, Times Square New York

Keynote Speakers

Kristopher Famm, Ph.D., President, Galvani Bioelectronics

Kris is president of Galvani Bioelectronics, being overall responsible for the company’s path to and delivery of bioelectronic medicines to patients. Before his appointment to lead Galvani Bioelectronics, he was founding VP and head of Bioelectronics R&D at GSK, which he launched in 2013. There he managed the unit’s extensive research towards establishing the treatment potential, disease reach and technology requirements for modulating signal patterns in visceral, peripheral nerves. He led the way in how we address these challenges on a global scale, too, working together with a network of research partners across academia and industry. During his time at GSK he also headed up the R&D Strategy Group and the Protein Degradation Discovery Performance Unit. Kris obtained his Ph.D. in molecular biology at University of Cambridge, following an M.Sc. in chemical engineering at Lund University, Sweden. Before joining GSK in 2009, he worked as a management consultant at McKinsey & Co.

Gene Civillico, Ph.D., Program Manager, National Institutes of Health

Gene F. Civillico, Ph.D., joined the NIH Office of Strategic Coordination in 2016 as Program Manager for the Stimulating Peripheral Activity to Relieve Conditions (SPARC) Program. Dr. Civillico earned his Ph.D. in neuroscience at the University of Pennsylvania School of Medicine, studying sensory integration in the rodent cerebral cortex using extracellular recording and voltage-sensitive dye imaging in vivo. He received postdoctoral training in cerebellar physiology and two-photon microscopy techniques at the Princeton Neuroscience Institute. In 2009 Dr. Civillico joined Otsuka Maryland, where, in partnership with an NIH-funded biotech firm, he led a small team using a novel functional screen to search for modulators of synaptic vesicle cycling in prefrontal cortical neurons in culture. Dr. Civillico moved to FDA’s Center for Devices and Radiological Health in 2011, where he developed a research portfolio targeted at common problems in the translation of neuroengineering research concepts into clinical solutions. Dr. Civillico maintains a research program in neural prosthetics at FDA/CDRH.

Eric Van Gieson, Ph.D., Program Manager, DARPA Biological Technologies Office

Dr. Eric Van Gieson joined DARPA as a Program Manager in August 2017 with the goal of using host-based methods to mitigate the impacts of emerging disease threats. He intends to explore epigenetic and real-time monitoring approaches that can dynamically guide healthcare decisions and therapy, and new methods of increasing patient survival in austere environments using intelligent systems partnered with local care providers. Throughout his career, Dr. Van Gieson has worked with private and interagency government partners to build diagnostic and healthcare solutions. For example, he leveraged those partnerships to develop a novel patient transport system known as the Containerized BioContainment System, a platform that received an “R&D 100” award and is currently in use by the Departments of State and Health and Human Services. He also created a university-based drug development pipeline to accelerate development of therapeutic products for guarding against WMD and emerging disease threats. His work has led to technology that links home-use and point-of-care diagnostics with health surveillance capabilities, especially in resource-limited environments, with the goal of stopping epidemics before they emerge. Dr. Van Gieson has also led technology development and evaluation efforts in diagnostics for the Department of Defense, and has supported major diagnostics acquisition and science and technology programs. Dr. Van Gieson received his Ph.D. in Biomedical Engineering and a Bachelor of Science degree in Chemical Engineering from the University of Virginia. He has published on topics ranging from genomic analysis to autonomous systems.

Conference Moderators

James Cavuoto, Editor and Publisher, Neurotech Reports

James Cavuoto is editor and publisher of Neurotech Business Report and the founder of Neurotech Reports. He is the lead author of "The Market for Neurotechnology," a market research report published by Neurotech Reports. Cavuoto was the founder of Micro Publishing Press, Inc., a publishing company that helped pioneer the market for electronic publishing, digital imaging, and computer graphics. He holds a degree in biomedical engineering from Case Western Reserve University, where he studied under pioneers in the field of functional electrical stimulation. He has also studied human factors engineering at University of Southern California in Los Angeles. Cavuoto spent three years as a member of the technical staff at Hughes Aircraft Company in Los Angeles, where he worked on simulation, training, and publication products produced for the U.S. Department of Defense. Cavuoto was an adjunct professor at Rochester Institute of Technology and the author of eight books on computer graphics, electronic publishing, and digital imaging. He is a member of the IEEE Engineering in Medicine and Biology Society. He has authored a chapter in the textbook Neuromodulation (Elsevier, 2009), as well as articles in Neuromodulation, Journal of Neural Engineering, Medical Device Daily, IEEE Spectrum, MX magazine, and the International Journal of Medical Marketing. He is coauthor, with Jennifer French, of Bionic Pioneers: Brave Neurotech Users Blaze the Trail to New Therapies (Neurotech Press, 2014).

Imran Eba, Partner, Action Potential Venture Capital

Imran is a partner at Action Potential Venture Capital in Cambridge, MA and invests in companies that are pioneering bioelectronic medicines and technologies. He represents Action Potential as a Board Member or Observer on the boards of Axon Therapies and SetPoint Medical. Before joining Action Potential, Imran was in the Worldwide Business Development group of GlaxoSmithKline working in a variety of business development and investing roles. Most recently, Imran led the establishment of and headed up the Investment Management practice at GlaxoSmithKline. The group was tasked with accessing technology and innovation external to GSK by making and managing investments in life science venture capital funds as limited partners and direct investments in biotechs made as part of GSK’s R&D collaborations. During his tenure the group led GSK’s commitments in excess of $200 million in a number of venture capital groups as well as participated in a number of biotech IPOs. Imran received his bachelor’s degree in finance from Concordia University in Montreal and has trained as a Canadian Chartered Accountant.

Jennifer French, Senior Editor and Associate Publisher, Neurotech Reports

Jennifer French is senior editor and associate publisher of Neurotech Reports. She is the founder of Neurotech Network, a nonprofit organization founded in Florida in 2003. Jennifer acquired her C6-7 incomplete spinal cord injury in 1998. Prior to her injury, she was recreationally active with such sports as canoeing, snowboarding/skiing, sailing, fly fishing, biking. After her injury, she still participates in all those activities. She is an active user of an FES system. Now residing in Tampa, FL, Jen is active in the community accessible sailing program, Sailing Alternatives as well as the national US Sailing, Sailors with Special Needs. French has helped launch successful divisions is such organizations as Bombardier Capital and PC Connection, Inc. With an MBA specializing in marketing & strategy, she works with for-profit and not-for-profit organizations, large and small, emerge into new markets, profile target customers and create and build systems to support sales efforts. She is the author of On My Feet Again (Neurotech Press, 2013), her personal story of rehabilitation using neurotechnology.

Jeremy Koff, Senior Contributing Editor, Neurotech Reports

Mr. Koff is senior contributing editor for Neurotech Reports and president of Colibri Partners Inc., a strategic and marketing consulting firm with a primary focus in the medical device sector. The company offers services related to market and risk analysis, clinical and technology assessments, business plan development, business/financial modeling, and market research. Mr. Koff has nearly 20 years of global experience in the medical device industry with companies including Advanced Bionics Corp., Boston Scientific, MiniMed Inc., Bioness Inc, and many others. His business plans have attracted tens of millions in start-up capital. Mr. Koff holds a Bachelor's degree in biology from Middlebury College, a Masters of Public Affairs from Indiana University, and an MBA from UCLA. He is an active classically-trained musician, supporter of the arts, and is a board member of the Fender Music Foundation.

Panelists and Presenters

Evan Norton, Divisional Vice President, Abbott Ventures

Evan Norton joined Abbott Ventures in 2010. Prior to Abbott Ventures, he was a Principal with ONSET Ventures focused on medical technology investing. He has a diverse background of experience in medical technology including the orthopedics, diabetes, and ear, nose, and throat markets. Evan also worked at Acclarent, Inc. and Johnson & Johnson’s diabetes company, LifeScan Inc. In addition to his medical device experience, Evan worked for Compaq Computer Corporation’s Strategic Investments group. Evan holds an MBA degree from the J.L. Kellogg Graduate School of Management and a BBA in Finance from Texas A&M University, cum laude.

Andrew ElBardissi, M.D., Principal, Deerfield Managment

Andrew ElBardissi is a healthcare venture investor at Deerfield Management in New York focusing on early to late venture investments in medical technology. Previously, he was a principal at Longitude Capital and prior to that was a healthcare investment banking associate at J.P. Morgan, where he led diligence and deal execution on equity, debt, and M&A transactions in biotech, med-tech, and healthcare services. Andrew earned his M.D. at Mayo Clinic, an MBA at Harvard Business School, and an MPH at Harvard School of Public Health. He was a Categorical General Surgery Resident at Brigham and Women's Hospital and later a Cardiothoracic Surgery Resident at Stanford University School of Medicine.

David Turkaly, Managing Director and Senior Research Analyst, JMP Securities

David Turkaly is a Managing Director and senior research analyst focused on the medical devices industry. Prior to joining JMP, David served as a senior research analyst at Susquehanna International Group, where he covered medical devices for six years. He was previously a Managing Director and senior analyst covering the medical devices industry at WR Hambrecht + Co. and a Director and senior analyst primarily following the neurological and orthopedic markets at CIBC World Markets Corp.  Earlier in his career, David worked in healthcare equity research at ING Barings and in healthcare investment banking at Smith Barney. David holds an MBA from Columbia Business School and a BS in accounting from University of Richmond.

Kadir Kadhiresan, Ph.D., Vice President, Venture Investments, J&J Development Corp.

V. Kadir Kadhiresan joined Johnson & Johnson Innovation - JJDC, Inc. in 2007 and focuses on investments in medical devices and digital health. Kadir has more than two decades of operational, investment, and business development experience. Based in Boston, Kadir works closely with Johnson & Johnson leadership to identify business needs and has responsibility for sourcing, investing and managing venture investment opportunities. He holds board seats for several JJDC portfolio companies. Some of his investments include Coherex Medical (Acquired by Biosense Webster/JNJ), Spinal Modulation (Acquired by St.Jude/ABT), Novocure (NASDAQ: NVCR), Torax Medical (Acquired by Ethicon/JNJ), and Neotract (Acquired by Teleflex). Before joining JJDC, Kadir was head of business development at Guidant, Inc., now Boston Scientific, Inc., where he led several transactions to access novel medical device technologies. Prior to entering business development, he led the research and development of multiple early-stage technologies and products in cardiac rhythm management and heart failure. Kadir was instrumental in the development of the cardiac resynchronization device for heart failure, now a multibillion dollar product. At Heart Rhythm Technologies, a subsidiary of Guidant, he led the development of an ablation technology for treatment of atrial fibrillation and raised venture financing for the project. Kadir has more than 40 issued patents and several scientific manuscripts published in top peer-reviewed journals. Kadir received a Ph.D. and M.S. in biomedical engineering from the University of Michigan, an MBA from the Kellogg School of Management at Northwestern University, and a B.S. in electrical engineering from National Institute of Technology, Trichy, India. Kadir was awarded the engineering alumni merit award from University of Michigan and serves on its biomedical engineering advisory board.

Edward Black, Founder and Managing Partner, Reimbursement Strategies, LLC

Before starting Reimbursement Strategies in 2008, Edward Black invested over 25 years in health and provider network management positions with Blue Cross Blue Shield working with hospitals and physicians in the upper Midwest. He also served on two national advisory boards responsible for leading consistency in medical, benefit, and payment policy throughout. From 1994 to 2002, Edward served as the executive director of three managed care business partnerships with large multispecialty clinics for which he was awarded the 1995 Outstanding Contribution to the Healthcare Industry Citation by Medical Alley (now LifeScience Alley).

Peter Staats, M.D., Founder and Chief Medical Officer, electroCore Medical LLC

Dr. Staats, a co-founder of electroCore, has been on the board of electroCore since its inception. He was the founder of the Division of Pain Medicine at Johns Hopkins University, where he was the director for 10 years. Dr. Staats is internationally recognized for his work in developing and implementing minimally invasive procedures for chronic pain, and his patents have led to the use of novel pharmacologic agents (Qutenza patch). Dr. Staats received his medical degree from the University of Michigan Medical School in Ann Arbor and completed his residency and fellowship training at the Johns Hopkins University School of Medicine. He is a past President of the North American Neuromodulation Society, American Society of Interventional Pain Physicians, New Jersey Society of Interventional Pain Physicians, and the Southern Pain Society. He is currently Chairman of the Board of Examination of the World Institute of Pain and continues to serve as Chief Medical Officer for National Spine and Pain Centers, the largest pain practice in the United States. Dr. Staats has written or co-edited 10 books and over 300 articles, abstracts, monographs, and book chapters on pain medicine in publications that include the Journal of the American Medicine Association, Pain, Anesthesiology, and the Journal of Clinical Oncology.

Chad Gibson, Managing Partner, CMD MedTech

Chad Gibson is a managing partner at CMD MedTech. He's a medical device product development expert with more than 17 years of relevant medical device experience. Chad's background includes systems engineering, regulatory and quality, and six sigma. He earned his degree and started his career in medical device electrical and software engineering. He has the RAPS RAC and ASQ CQA certifications. Chad is an inventor on 13 US patents in the fields of medical devices and health software.

Entrepreneur Presenters

Milton Morris, Ph.D., CEO, NeuSpera Medical Inc.

Milton Morris was appointed CEO of NeuSpera Medical in 2015. Dr. Morris was recently senior vice president of research and development at Cyberonics, Inc., where he had responsibilities for research, product development, advanced manufacturing engineering, program management, and emerging therapies. During his six-year tenure, the company received regulatory approvals for three implantable neuromodulation devices and a fourth wearable device that provides remote monitoring of patients with epilepsy. One of these new products contains a fundamental advancement to the company’s core therapy – closed-loop vagus nerve stimulation therapy for epilepsy while two others enable the company to enter into two large markets, heart failure and mobile health. Dr. Morris joined Cyberonics from InnerPulse Corp., a medical device startup company in the Research Triangle Park of North Carolina, where he served as director, program management and operations. Prior to InnerPulse, Dr. Morris was employed by Guidant Corp. and its successor, Boston Scientific Corp.. During his 11-year tenure, he held several positions, including director, marketing, where he served as the $1.6B arrhythmia franchise leader with responsibilities for both the implantable pacemaker and defibrillator businesses for the Cardiac Rhythm Management division. Dr. Morris holds a Master’s in Business Administration from the Kellogg School of Management and a Ph.D. in electrical engineering from the University of Michigan.

Nader Yaghoubi, M.D., Ph.D., President and CEO, PathMaker Neurosystems Inc.

Dr. Yaghoubi has over 20 years of experience in the creation, operations, and financing of life science companies. Before starting PathMaker Neurosystems, he established, as president and Founding CEO, Symbiotix Biotherapies, a pioneering microbiome company developing novel molecular therapeutics based on the human microbiome. Prior to that, he was the first employee at Selecta Biosciences and BIND Therapeutics, where he worked with the founders to launch the companies and establish operations and corporate development. Previously, he was at Zero Stage Capital, a venture capital firm where he was responsible for investing in the life sciences sector, and earlier completed an internship at Advent International. Prior to this, he was a Health Care Entrepreneurship Fellow at Boston University, where he worked with scientists and physicians to develop new businesses in the healthcare and life science sector. Before his fellowship, he was a surgical resident in the Department of Surgery at Lenox Hill Hospital in New York. Dr. Yaghoubi received an M.D. and Ph.D. in Molecular Pharmacology from the combined degree program at Boston University School of Medicine. His doctorate work on the development of high-throughput automated electrophysiological systems resulted in five issued U.S. patents, received one of the University’s highest awards for dissertational research, and was the basis of a venture-backed biotechnology company focused on neuroscience. He is extensively involved in mentoring young companies, and has served/serves as a mentor, advisor and reviewer with MBC’s MassCONNECT program, Mass Life Sciences Center programs, Springboard Venture Capital Forum, and numerous university business plan competitions.

James Ross, Ph.D., Co-Founder and CTO, Axion Biosystems

Jim Ross is the CTO and co-founder of Axion Biosystems. Previously, he was a product development engineer for Advanced Micro Devices and the co-founder of Nanogrip Technologies, maker of micro-scale devices used to manipulate MEMs components. He has over 15 years of experience in MEMS fabrication, analog circuit design, and neural interfacing technology. During this time, he has been instrumental in producing over a dozen critically enabling technologies for the manipulation and sensing of neural tissue. Jim received a Bachelor of Science degree in Electrical Engineering from Louisiana State University and a Doctorate in Bioengineering from Georgia Tech.

Tina Chang, Director of International Business, GiMer Medical

Tina Chang is Director of International Business at GiMer Medical, a Taiwan-based neurostimulation startup. Prior to joining GiMer Medical, most recently Tina served as OEM manager for a medical device manufacturer. In earlier years, she engaged in clinical work at a New York City hospital. After obtaining an MBA, she gained international business exposure from large corporations like Colgate-Palmolive (NYC/Taipei), as well as from various consulting boutiques in Shanghai. Her aspiration lies in helping Taiwanese startups to grow and glow internationally.

Jörn Ricket, Ph.D., CEO, CorTec GmbH

Jörn Rickert studied biology in Hamburg and Freiburg. His dissertation on the representation of movement in the motor cortex made an important contribution to basic neurobiological research. When writing his dissertation, he also had the idea to use scientific research as a bridge for implementation and to start a business focusing thereon. After completing his PhD in 2004, he became project manager at the Brain Machine Interfacing Initiative in Freiburg, undertaking the task of transferring the research results of this group of scientists into a marketable product. Since the foundation of CorTec in September 2010 he has been the company’s CEO.

Ana Maiques, CEO Neuroelectrics

Ana Maiques is the CEO of Neuroelectrics, a company aiming to change the way we interact with the brain; developing innovative technologies to monitor and stimulate the brain. She was nominated by IESE as one of the most influential entrepreneurs under 40 in Spain in 2010; she was the only woman on that list. She received the EU Prize for Women Innovators from the European Commission EC in 2014. Also in 2014, she was an award recipient of the International Women’s Entrepreneurial Challenge. In 2015 and 2016, she was named one of most inspiring women on the Inspiring Fifty list in Europe of women technological leaders and innovators. As a company, Neuroelectrics received the Best Start-up in Health Award in 2015 by Wired UK magazine and in 2016 was recognized as one of the “Best Entrepreneurial Companies in America” by Entrepreneur Magazine’s Entrepreneur 360 List. Ana continues to break the barriers for women and entrepreneurs bringing together science and technology in an impactful way.

Nadim Yared, President and CEO, CVRx Inc.

Nadim Yared is the President and CEO of CVRx. Mr. Yared had previously served as Vice President and General Manager of Medtronic Navigation, the leading supplier of integrated image-guided surgery products in the world, from 2002 to 2006. He also worked at GE Medical for 10-years, where he had been Vice President of Global Marketing for the OEC Medical Systems and Vice President and General Manager of GE’s European X-ray business based in Paris. Mr. Yared has an engineering degree from Ecole Nationale Supérieure des Télécommunications, and an MBA from INSEAD, France. Mr. Yared is a member of the Board of Directors for AdvaMed, MDIC, and CVRx. In addition, he recently served as the chairman of the AdvaMed Accel Board and he is currently the chairman of the AdvaMed Board of Directors.

Allen Braswell, CEO, Magneceutical Health

Allen Braswell is the President of Magneceutical Health. He has a background in finance and law and a 25-year track record in starting, building, and operating small companies and growing them into large, successful businesses. Mr. Braswell spent most of his career leading Circuit Test Inc, a computer service company with over 15 Fortune 500 customers such as. IBM, Apple, Toshiba, Sony, Cisco Systems, Hewlett Packard, and Sun Microsystems, along with two Fortune 500 Strategic Partners (FedEx and UPS) in changing the landscape of computer service logistics, by combining his company's technical repair capability within the “hub” locations of FedEx and UPS. While there, he led four M&A transactions (two selling and two purchase events) before finally retiring from Jabil Circuit, a tier one company in the Electronic Manufacturing Services arena that ultimately acquired Circuit Test. He is skilled at attracting and developing the highly talented management teams successful start-ups require. Mr. Braswell has spent the last several years as a member of the Boards of Directors of two publicly traded companies, gaining valuable experience in the strategy, governance, and performance expectations that the public markets require. Mr. Braswell attended the U.S. Military Academy (West Point) and graduated from the University of Florida with a Bachelor's degree in Finance. He received his J.D. degree from University of Florida School of Law.

Christpher Czura, Ph.D., Vice-President, Scientific Affairs, Feinstein Institute for Medical Research

Christopher J. Czura is Vice President of the Feinstein Institute for Medical Research, executive publisher of the Feinstein Institute Press’ international, peer-reviewed journals Molecular Medicine and Bioelectronic Medicine, executive producer of the Merinoff Conference Series, and Chief Financial Officer for the Elmezzi Graduate School of Molecular Medicine. Dr. Czura provides oversight of the Institute’s daily operations and $95 million annual budget. He collaborates with the president to develop and execute strategic plans for the Institute, and is committed to building successful programs that nurture the collaborative and interactive environment of the Feinstein Institute. He leads project teams in the design and oversight of construction of new laboratory facilities and renovation projects. A molecular biologist by training, Dr. Czura’s research interests focus on autonomic neural regulation of hemostasis and inflammation. He received his B.S. in biotechnology from William Paterson University in 1996 and a doctoral degree in molecular microbiology from Stony Brook University in 2009. He is author or co-author of approximately 80 peer-reviewed publications, book chapters, and meeting abstracts, and co-inventor on a patent that describes vagus nerve stimulation to control hemorrhage. Dr. Czura began his research career in the laboratory of Dr. Kevin Tracey, studying the mechanisms of pathological inflammation. Dr. Czura has also studied the inflammatory reflex, a neural mechanism through which the central nervous system detects and regulates immune responses to infection and injury. More recently, Dr. Czura and his colleagues Dr. Tracey and Dr. Jared Huston have made discoveries in the field of bioelectronic medicine. His primary work in this field led to the discovery of the “neural tourniquet,” a field of technology that uses electrical nerve stimulation to control traumatic hemorrhage.

site design by shalatdesign | shalat.com